NHD Global
Metabolic & Weight Loss · GIP/GLP-1 research
Scientific Product Dossier
Tirzepatide is a 39-amino-acid peptide with dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist activity. Human clinical trials and FDA-approved branded medicines provide substantial compound-level evidence, but catalog research material is not an FDA-approved drug and is not intended for human use.
Shared values below are consolidated from the current catalog record. They are not independent verification or lot results; the current product specification and lot COA control.
Product identity
Literature reference parameters
Identity safeguard Reference identifiers above describe the literature compound record. The supplied form, formula, molecular weight, purity and storage conditions must be verified against the product-specific specification and lot COA.
A target-to-pathway view grounded in the linked research records.
Reported research findings
Reported outcomes are paired with their experimental model and evidence boundary.
At 72 weeks, the published trial reported mean weight changes of −15.0%, −19.5% and −20.9% across three tirzepatide groups, compared with −3.1% for placebo.
Human trial of a studied pharmaceutical intervention; results do not establish identity, safety or efficacy of this catalog research material.
Read the primary studyThe current FDA label identifies tirzepatide as a GIP/GLP-1 receptor agonist and records initial U.S. approval in 2022.
Approval applies only to the named regulated drug product and presentation, not to third-party research material.
Read the primary studyCurrent U.S. labeling includes a boxed warning based on thyroid C-cell tumor findings in rats, contraindications and common gastrointestinal adverse reactions.
This safety information belongs to the named regulated finished drug; it neither validates nor characterizes third-party catalog material.
Read the primary studyThe trial randomized 2,539 adults without diabetes. At week 72, mean weight change was −15.0%, −19.5% and −20.9% in the 5, 10 and 15 mg study groups, versus −3.1% with placebo.
The treatment-regimen estimand included effects regardless of discontinuation. Gastrointestinal events were common; adverse-event discontinuation was 4.3%, 7.1% and 6.2% versus 2.6% with placebo. These data concern the studied intervention.
Read the primary studyCatalog options
Pack-level catalog data; lot-level controls remain document-specific.
Single-component peptide · 5 mg/vial nominal · 10-vial pack · supplied form and release limits controlled by lot specification.
Request by lot: CoA, HPLC purity and MS identity
Single-component peptide · 10 mg/vial nominal · 10-vial pack · supplied form and release limits controlled by lot specification.
Request by lot: CoA, HPLC purity and MS identity
Single-component peptide · 15 mg/vial nominal · 10-vial pack · supplied form and release limits controlled by lot specification.
Request by lot: CoA, HPLC purity and MS identity
Single-component peptide · 20 mg/vial nominal · 10-vial pack · supplied form and release limits controlled by lot specification.
Request by lot: CoA, HPLC purity and MS identity
Single-component peptide · 30 mg/vial nominal · 10-vial pack · supplied form and release limits controlled by lot specification.
Request by lot: CoA, HPLC purity and MS identity
Single-component peptide · 40 mg/vial nominal · 10-vial pack · supplied form and release limits controlled by lot specification.
Request by lot: CoA, HPLC purity and MS identity
Single-component peptide · 50 mg/vial nominal · 10-vial pack · supplied form and release limits controlled by lot specification.
Request by lot: CoA, HPLC purity and MS identity
Single-component peptide · 60 mg/vial nominal · 10-vial pack · supplied form and release limits controlled by lot specification.
Request by lot: CoA, HPLC purity and MS identity
Single-component peptide · 100 mg/vial nominal · 10-vial pack · supplied form and release limits controlled by lot specification.
Request by lot: CoA, HPLC purity and MS identity
Single-component peptide · 120 mg/vial nominal · 10-vial pack · supplied form and release limits controlled by lot specification.
Request by lot: CoA, HPLC purity and MS identity
Document availability is stated honestly and can vary by catalog variant or lot.
Analytical interpretation
Use the source-reviewed guide to separate chromatographic area purity, quantitative assay, LC-MS identity, composition and stability evidence before comparing variants or requesting a lot record.
Open the Quality & Documentation HubHPLC area ≠ assayA dominant peak does not establish target mass fraction.
Intact mass ≠ full sequenceIdentity strength depends on resolution and orthogonal evidence.
Counterions affect contentWater, salt form and solvents change the as-is composition.
Storage needs a data basisShipping practice is not the same as stability evidence.
Evidence map
Published studies and regulatory records, not customer testimonials or usage guidance.
Randomized, double-blind, placebo-controlled human research over 72 weeks. Results are clinical evidence for the studied intervention, not a specification for this catalog lot.
View primary recordAuthoritative pharmacology and approval context for a regulated branded medicine. The research catalog remains physically and legally distinct.
View primary recordThird-party publications selected for direct relevance.
Jastreboff AM, et al. N Engl J Med. 2022;387:205–216. PMID 35658024.
U.S. Food and Drug Administration. Revised December 2025. Initial U.S. approval 2022.
U.S. Food and Drug Administration. Current Drugs@FDA label for NDA 217806.
Concise answers for researchers comparing identity, evidence and catalog variants.
Tirzepatide is a 39-amino-acid peptide that acts as a dual GIP and GLP-1 receptor agonist.
The 72-week Phase 3 trial reported substantial mean body-weight reductions across studied tirzepatide groups. Those results apply to the controlled clinical intervention and do not validate a catalog research lot.
No. FDA approval applies to specific regulated branded products. This catalog entry is research, development and manufacturing material only.
A lot-specific COA, product specification sheet and analytical method summary can be requested where applicable.
Store at -20 °C, protected from light and moisture. After reconstitution, aliquot and avoid repeated freeze-thaw cycles. Confirm the applicable storage statement on the product-specific specification and lot documentation.
Knowledge center
Owned educational content connected to this family.
An evidence-led explanation of tirzepatide dual receptor agonism and the endpoints measured in SURPASS and SURMOUNT trials, with clear limits on applying drug data…
Updated August 28, 2026
Why an FDA-approved tirzepatide medicine, a compounded product and a research-use catalog material are not interchangeable evidence categories.
Updated August 28, 2026Source-traceable evidence
Structured readings of published studies, with the model, result and translation boundary stated explicitly.
A structured reading of the SURMOUNT-1 Phase 3 trial, preserving the randomized design, four-group results, discontinuation data and the distinction between an approved finished drug and…
Knowledge tools
Move from this dossier into canonical evidence maps, verified status records, analytical interpretation and laboratory calculations.
Published-study results are tied to the linked records and kept separate from catalog-lot claims. Imported purity, storage and document-availability templates have been removed pending product- and lot-specific confirmation.
Technical procurement
Selected: TR30 · 30 mg × 10 vials
Tell us what you need. Your enquiry will be routed to the appropriate contact for catalog numbers, availability and quotation details.
